Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 9/20 | 0.50 |
| ▸ | BCL2 | P10415 | 16/20 | 0.42 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498862 | 1.00 | BCL2L1 (0.50) | BCL2L1BCL2BCL2L11CYP2C9MCL1 | |
| SCHEMBL2493656 | 0.89 | BCL2L1 (0.54) | BCL2L1BCL2 | |
| SCHEMBL13332630 | 0.88 | BCL2L1 (0.45) | BCL2L1BCL2BCL2L11CYP2C9MCL1 | |
| SCHEMBL2493411 | 0.77 | BCL2L1 (0.45) | BCL2L1BCL2 | |
| SCHEMBL13332632 | 0.76 | BCL2L1 (0.48) | BCL2L1BCL2BCL2L11CYP2C9MCL1 | |
| SCHEMBL2494348 | 0.75 | MRGPRX4 (0.42) | BCL2MCL1 | |
| SCHEMBL15826886 | 0.75 | MRGPRX4 (0.42) | BCL2MCL1 | |
| SCHEMBL2494352 | 0.75 | MRGPRX4 (0.42) | BCL2MCL1 | |
| SCHEMBL2496992 | 0.75 | BCL2L1 (0.55) | BCL2L1BCL2BCL2L11CYP2C9MCL1 | |
| SCHEMBL2493081 | 0.70 | BCL2L1 (0.51) | BCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2373629-B1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-2373629-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BCL2, BAX, BCL2A1 | BCL2L1 5/4885BCL2 1/4885BCL2L11 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.